This week, six capital markets stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy"). More
5 Stocks With Poor Sales Growth — HTS MITT UEC LPCN MNKD
This week, these five stocks have the worst ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader. More
5 Stocks With Awful Operating Margin Growth — NBIX CTEL TSRA NYNY PMFG
This week, these five stocks have the worst ratings in Operating Margin Growth, one of the eight Fundamental Categories on Portfolio Grader. More
Generic Drug Stocks Soar – Your Best Healthcare Plays Are TEVA and MYL
Mylan just announced a deal to buy Abbott Labs' global generics business. MYL stock is popping now, but should run for some time thanks to the big tailwind that generic drug stocks are getting right now. More
Dow 17,000 Doesn’t Matter – Morning Linkfest (July 14)
Market milestones, Dow 17,000 and craft beer all in today's Linkfest from InvestorPlace More
3 Biotech Stocks That Belong in Your Portfolio
The recent pullback in biotech stocks is an opportunity for investors to appeal to both growth and value in this dynamic sector. More
3 Road and Rail Stocks to Sell Now
For the current week, the overall ratings of three road and rail stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell"). More
